A072520 Stock Overview
Operates in the bio industry in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
GenNBio Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩389.00 |
| 52 Week High | ₩880.00 |
| 52 Week Low | ₩352.00 |
| Beta | 0.96 |
| 1 Month Change | 0% |
| 3 Month Change | -0.51% |
| 1 Year Change | -43.29% |
| 3 Year Change | -95.48% |
| 5 Year Change | -96.25% |
| Change since IPO | -98.81% |
Recent News & Updates
Shareholder Returns
| A072520 | KR Healthcare | KR Market | |
|---|---|---|---|
| 7D | 0% | -7.1% | -0.5% |
| 1Y | -43.3% | -26.0% | -11.6% |
Return vs Industry: A072520 underperformed the KR Healthcare industry which returned -11.3% over the past year.
Return vs Market: A072520 underperformed the KR Market which returned 4.5% over the past year.
Price Volatility
| A072520 volatility | |
|---|---|
| A072520 Average Weekly Movement | n/a |
| Healthcare Industry Average Movement | 10.3% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in KR Market | 12.7% |
| 10% least volatile stocks in KR Market | 3.3% |
Stable Share Price: A072520 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine A072520's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 76 | n/a | www.gennbio.com |
GenNBio Inc. operates in the bio industry in South Korea. It engages in the research and development of xenogeneic organs; conducts non-clinical trial service on primates and rodents; development of artificial organs and new drugs; and is involved in pharmaceutical and medical device distribution business; as well as operates a transplant hospital. The company also offers xenotransplantation process, which is transplanting cells, organs, tissues, etc. from animals to humans.
GenNBio Inc. Fundamentals Summary
| A072520 fundamental statistics | |
|---|---|
| Market cap | ₩28.84b |
| Earnings (TTM) | -₩16.65b |
| Revenue (TTM) | ₩2.69b |
10.7x
P/S Ratio-1.7x
P/E RatioIs A072520 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A072520 income statement (TTM) | |
|---|---|
| Revenue | ₩2.69b |
| Cost of Revenue | ₩2.65b |
| Gross Profit | ₩42.28m |
| Other Expenses | ₩16.69b |
| Earnings | -₩16.65b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -224.58 |
| Gross Margin | 1.57% |
| Net Profit Margin | -618.43% |
| Debt/Equity Ratio | 33.1% |
How did A072520 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/06/18 11:30 |
| End of Day Share Price | 2024/03/21 00:00 |
| Earnings | 2024/03/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
GenNBio Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mok Hyun Ji | MERITZ Securities Co., Ltd. |
| Sang-Yong Jeon | SK Securities Co., Ltd. |